4 min read

A pharmacist's guide to the Swiss therapeutic products framework

Swiss medicines law can look like an alphabet soup: HMG, VAM, AMBV, AMZV, KlinV. Behind the abbreviations is a clear structure. One federal act sets the principles, and a set of ordinances spells out the detail for each part of a medicine's life.
A pharmacists guide to the Swiss therapeutic products framework

Swiss medicines law can look like an alphabet soup: HMG, VAM, AMBV, AMZV, KlinV. Behind the abbreviations is a clear structure. One federal act sets the principles, and a set of ordinances spells out the detail for each part of a medicine's life.

As a pharmacist with a Swiss federal licence, I apply parts of this framework every day. My MSc module on Regulatory Aspects for Approval of Therapeutics covered the parts that govern industry. This article maps how the pieces fit together.

The foundation: the Therapeutic Products Act (HMG)

The Heilmittelgesetz (HMG), or Therapeutic Products Act, is the core federal law for medicinal products and medical devices (Therapeutic Products Act [TPA], 2000). Its purpose is to ensure that only high-quality, safe and effective therapeutic products are placed on the market.

The HMG covers authorisation, manufacturing, distribution, prescribing and dispensing, advertising, market surveillance and pharmacovigilance. It also establishes Swissmedic, the Swiss Agency for Therapeutic Products, as the national authority (TPA, 2000).

The key ordinances

OrdinanceEnglish nameWhat it governs
VAMMedicinal Products OrdinanceAuthorisation procedures, dispensing categories, pharmacovigilance, product information (Medicinal Products Ordinance [VAM], 2018)
AMBVMedicinal Products Licensing OrdinanceLicences for manufacturing, wholesale, import and export; GMP and GDP requirements (Medicinal Products Licensing Ordinance [AMBV], 2018)
AMZVOrdinance on Requirements for AuthorisationContent and format of authorisation documentation (Ordinance on the Requirements for Authorisation [AMZV], 2001)
AWVMedicinal Products Advertising OrdinanceAdvertising to professionals and the public (Medicinal Products Advertising Ordinance [AWV], 2001)
KlinVClinical Trials OrdinanceClinical trials of medicinal products, under the Human Research Act (Clinical Trials Ordinance [KlinV], 2013)

Other laws also matter in practice, such as the Narcotics Act (BetmG) for controlled substances (Narcotics Act [BetmG], 1951).

The VAM: what pharmacists meet most often

For community pharmacists, the VAM is the ordinance closest to daily work. It defines the dispensing categories that decide who may supply a medicine.

Since the 2019 revision of the law, there are four categories: A and B require a prescription, D requires specialist advice from a pharmacist or druggist, and E can be sold freely. The previous category C was abolished, and many products moved to categories B or D (VAM, 2018).

The revision also gave pharmacists the right to dispense certain prescription-only (category B) medicines without a prescription, under defined conditions and with documentation (TPA, 2000, Art. 24; VAM, 2018). This expanded the pharmacist's role in primary care and in medication safety.

The VAM also sets out pharmacovigilance obligations, including the reporting of suspected adverse reactions to Swissmedic (VAM, 2018).

The AMBV: licences and Good Practices

The AMBV regulates the companies that make and move medicines. Manufacturers, wholesalers, importers and exporters need a licence from Swissmedic (AMBV, 2018).

Licensed companies must follow Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP), which in Switzerland are aligned with the PIC/S and EU guidelines (AMBV, 2018). Each establishment needs a responsible person, the fachtechnisch verantwortliche Person, who is accountable for compliance, including batch release in manufacturing.

Hospital pharmacies and compounding pharmacies that manufacture medicines also fall under these rules, depending on the scale and type of manufacturing.

Who enforces what

Responsibilities are shared between federal and cantonal levels:

  • Swissmedic authorises medicines, licenses manufacturers and wholesalers, inspects them, and runs market surveillance and pharmacovigilance.
  • The cantons license public and hospital pharmacies, oversee the professional practice of pharmacists and doctors, and carry out pharmacy inspections, usually through the cantonal pharmacist (TPA, 2000).

This split is important for anyone moving from pharmacy into industry. The obligations change, but the underlying principles of quality, traceability and patient safety remain the same.

How this framework shows up at the pharmacy counter

In my work at Coop Vitality, regulatory compliance runs through daily tasks:

  • checking that prescriptions are valid and that the correct dispensing category is respected;
  • documenting advice and dispensing decisions where the law requires it;
  • storing medicines under the right conditions and managing expiry dates;
  • handling controlled substances according to the Narcotics Act;
  • identifying, documenting and escalating suspected adverse reactions.

At Amavita in Bülach, I also supported regulatory compliance in prescription handling and pharmaceutical inventory management.

Why this matters to employers

Companies operating in Switzerland need people who understand the Swiss framework, not only the EU model. Regulatory affairs, quality assurance and pharmacovigilance teams all rely on knowing which ordinance applies, which authority is responsible and what the practical obligations are.

My experience applying Swiss medicines law in practice, combined with regulatory training at the University of Basel, gives me a solid foundation for these roles.

Key takeaways

  • The HMG sets the principles; ordinances such as VAM, AMBV and AMZV provide the detail.
  • Swissmedic oversees products and companies; the cantons oversee pharmacies and professionals.
  • The same principles of quality, traceability and safety apply from manufacturer to pharmacy counter.

References

Clinical Trials Ordinance [KlinV] of 20 September 2013, SR 810.305 (Switzerland). https://www.fedlex.admin.ch

Medicinal Products Advertising Ordinance [AWV] of 17 October 2001, SR 812.212.5 (Switzerland). https://www.fedlex.admin.ch

Medicinal Products Licensing Ordinance [AMBV] of 14 November 2018, SR 812.212.1 (Switzerland). https://www.fedlex.admin.ch

Medicinal Products Ordinance [VAM] of 21 September 2018, SR 812.212.21 (Switzerland). https://www.fedlex.admin.ch

Narcotics Act [BetmG] of 3 October 1951, SR 812.121 (Switzerland). https://www.fedlex.admin.ch

Ordinance on the Requirements for Authorisation [AMZV] of 9 November 2001, SR 812.212.22 (Switzerland). https://www.fedlex.admin.ch

Therapeutic Products Act [TPA] of 15 December 2000, SR 812.21 (Switzerland). https://www.fedlex.admin.ch